All News
-
Destiny Pharma announces research collaboration with Aston University to investigate new XF-platform drug candidates
Read MoreResearch to investigate potential antimicrobial candidates against biofilms
-
ANTABIO Completes € 12.5M Series A
Read MoreNew investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017
-
Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
Read MoreNon-Dilutive Funding Could Support Development through Completion of a Phase 1 Clinical Trial
-
Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program
Read MoreSecond recent transaction with Bravos Biosciences consolidates development of Arsanis gram-negative mAb candidates with global experts in anti-infective drug development
-
ASM Microbe 2018: Nosopharm to present new first-inclass clinical candidate to tackle interobacteriaceae infections
Read MoreNOSO-502 is on track to be the first novel antibiotic class for the Enterobacteriaceae infections to be introduced into the clinics for 40 years. First-In-Human (FIH) studies are expected to start in 2020
-
Nosopharm renews its partnership with Inra
Read MoreThis second screening campaign aims to discover new classes ofantimicrobial agents for treating multi-resistant infections
-
MOTIF BIO REVIVE-2 PHASE 3 STUDY RESULTS WITH ICLAPRIM PUBLISHED IN PEER-REVIEWED JOURNAL, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Read MoreIclaprim met the primary endpointIclaprim was well tolerated in the study, with no nephrotoxicity observedAdditional data from the previously announced results are included in the publication